Elagolix: An Investigational Treatment for Uterine Fibroids

Gonadotropin-releasing hormone, or GnRH, is a peptide that stimulates the secretion of the pituitary hormones that are responsible for sex steroid production and normal reproductive function.

Elagolix is an orally active, nonpeptide GnRH antagonist, being investigated for the treatment of uterine fibroids.  It is believed that elagolix may be able to alter the level of pituitary GnRH suppression thereby titrating circulating hormone levels and may provide patients relief from the painful symptoms of endometriosis while avoiding the need for the active management of bone loss.